ADVICOR contains niacin extended-release and lovastatin in combination. Niacin, a B-complex vitamin, and lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, are both lipid-altering agents.
ADVICOR is a fixed-dose combination product and is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION). Therapy with lipid-altering agents should be only one component of multiple risk-factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Initial medical therapy is indicated with a single agent as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also Table 7 and the NCEP treatment guidelines1).
ADVICOR is indicated for the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb; Table 6) in:
Patients treated with lovastatin who require further TG-lowering or HDL-raising who may benefit from having niacin added to their regimen
Patients treated with niacin who require further LDL-lowering who may benefit from having lovastatin added to their regimen
Published Studies Related to Advicor (Lovastatin)
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib.Our results suggest that the addition of lovastatin to the TD regimen may improve the response rate in patients with relapsed or refractory myeloma.
Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease. [2011.02]
OBJECTIVE: Emerging evidence assumes that statins have a benefit to influence the myocardial remodeling and ischemia in patients with coronary artery disease (CAD). Our aim was to investigate the possible and direct favorable effects of lovastatin on left ventricular (LV) systolic, diastolic function and myocardial ischemia in patients with CAD... CONCLUSION: Lipid-lowering therapy with lovastatin improved the LV systolic function and decreased myocardial ischemia.
Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]
BACKGROUND: Lovastatin is an inhibitor of P-glycoprotein (P-gp) and is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme. Verapamil is a substrate of both P-gp and CYP3A4. It is therefore likely that lovastatin can alter the absorption and metabolism of verapamil... CONCLUSION: Lovastatin increased the absorption of verapamil by inhibiting P-gp and inhibited the first-pass metabolism of verapamil by inhibiting CYP3A4 in the intestine and/or liver in humans.
Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. [2010.01]
BACKGROUND: Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied... CONCLUSIONS: Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Effect of niacin ER/lovastatin on claudication symptoms in patients with
peripheral artery disease. 
In patients with peripheral artery disease (PAD), statins may improve the
symptoms of claudication. The Intermittent Claudication Proof of Principle
(ICPOP) study tested the hypothesis that the combination of extended release
niacin plus lovastatin would improve exercise performance in patients with PAD
and claudication compared with a diet intervention...
Clinical Trials Related to Advicor (Lovastatin)
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC [Completed]
The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin,
Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of
their leg arteries.
At least 870 subjects, with leg pain caused by a narrowing of their leg arteries will take
part in this study.
Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug
Administration (FDA) to treat high cholesterol. Niacin ER/Lovastatin (Advicor®), a
combination of these two drugs, is also approved by the FDA to treat high cholesterol. The
use of Niacin ER/Lovastatin to treat narrowing of leg arteries and relieve “intermittent
claudication” (leg pain caused by narrowing of the arteries in the leg) is considered
investigational. An investigational use is one that is not approved by the FDA.
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication [Completed]
The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses,
compared to diet control (this group will receive a tablet containing 50 mg. of
immediate-release niacin) is a safe and effective medicine in subjects with leg pain caused
by a narrowing of their leg arteries, a condition called intermittent claudication.
At least 366 subjects with leg pain caused by a narrowing of their leg arteries will
participate in this study.
Niacin ER/Lovastatin is a combination of two FDA (United States Food and Drug Administration)
approved cholesterol modifying medications: Niaspan® (extended-release niacin) and
lovastatin, a statin (the same medicine found in Mevacor®). Niacin ER/Lovastatin was approved
by the FDA under the name of Advicor® for use in the treatment of elevated cholesterol. The
use of Niacin ER/Lovastatin in the treatment of peripheral arterial disease and symptomatic
relief of intermittent claudication is considered investigational. An investigational use is
one that is not approved by the FDA.
Reports of Suspected Advicor (Lovastatin) Side Effects
Blood Cholesterol Abnormal (1),
Liver Injury (1),
Blood Creatine Phosphokinase Increased (1),
Product Contamination Microbial (1),
Stent Placement (1),
Erythema (1), more >>